Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer

NCT05985330 · clinicaltrials.gov ↗

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non-small Cell Lung Cancer

Interventions

OTHER: Measurement of FeNO

Sponsor

Centre Hospitalier Universitaire Dijon